PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Morotti, M.* ; Grimm, A.J.* ; Hope, H.C.* ; Arnaud, M.* ; Desbuisson, M.* ; Rayroux, N.* ; Barras, D.* ; Masid, M.* ; Murgues, B.* ; Chap, B.S.* ; Ongaro, M.* ; Rota, I.A.* ; Ronet, C.* ; Minasyan, A.* ; Chiffelle, J.* ; Lacher, S.B.* ; Bobisse, S.* ; Murgues, C.* ; Ghisoni, E.* ; Ouchen, K.* ; Bou Mjahed, R.* ; Benedetti, F.* ; Abdellaoui, N.* ; Turrini, R.* ; Gannon, P.O.* ; Zaman, K.S.* ; Mathevet, P.* ; Lelievre, L.* ; Crespo, I.* ; Conrad, M. ; Verdeil, G.* ; Kandalaft, L.E.* ; Dagher, J.* ; Corria-Osorio, J.* ; Doucey, M.A.* ; Ho, P.C.* ; Harari, A.* ; Vannini, N.* ; Böttcher, J.P.* ; Dangaj Laniti, D.* ; Coukos, G.*

PGE2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function.

Nature 629, 426-434 (2024)
Verlagsversion DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Expansion of antigen-experienced CD8+ T cells is critical for the success of tumour-infiltrating lymphocyte (TIL)-adoptive cell therapy (ACT) in patients with cancer1. Interleukin-2 (IL-2) acts as a key regulator of CD8+ cytotoxic T lymphocyte functions by promoting expansion and cytotoxic capability2,3. Therefore, it is essential to comprehend mechanistic barriers to IL-2 sensing in the tumour microenvironment to implement strategies to reinvigorate IL-2 responsiveness and T cell antitumour responses. Here we report that prostaglandin E2 (PGE2), a known negative regulator of immune response in the tumour microenvironment4,5, is present at high concentrations in tumour tissue from patients and leads to impaired IL-2 sensing in human CD8+ TILs via the PGE2 receptors EP2 and EP4. Mechanistically, PGE2 inhibits IL-2 sensing in TILs by downregulating the IL-2Rγc chain, resulting in defective assembly of IL-2Rβ-IL2Rγc membrane dimers. This results in impaired IL-2-mTOR adaptation and PGC1α transcriptional repression, causing oxidative stress and ferroptotic cell death in tumour-reactive TILs. Inhibition of PGE2 signalling to EP2 and EP4 during TIL expansion for ACT resulted in increased IL-2 sensing, leading to enhanced proliferation of tumour-reactive TILs and enhanced tumour control once the cells were transferred in vivo. Our study reveals fundamental features that underlie impairment of human TILs mediated by PGE2 in the tumour microenvironment. These findings have therapeutic implications for cancer immunotherapy and cell therapy, and enable the development of targeted strategies to enhance IL-2 sensing and amplify the IL-2 response in TILs, thereby promoting the expansion of effector T cells with enhanced therapeutic potential.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
50.500
0.000
5
1
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Tumor-infiltrating Lymphocytes; T-cells; Immunotherapy; Biogenesis; Activation; Therapy; Pathway
Sprache englisch
Veröffentlichungsjahr 2024
HGF-Berichtsjahr 2024
ISSN (print) / ISBN 0028-0836
e-ISSN 1476-4687
Zeitschrift Nature
Quellenangaben Band: 629, Heft: 8011, Seiten: 426-434 Artikelnummer: , Supplement: ,
Verlag Nature Publishing Group
Verlagsort London
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Metabolism and Cell Death (MCD)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Genetics and Epidemiology
PSP-Element(e) G-506900-001
Förderungen Center of Experimental Therapies (CTE)
Biltema Foundation
Paul Matson Foundation
Cancera Foundation
Swiss Cancer League Foundation
German Research Foundation (DFG)
Ludwig Institute for Cancer Research
DOI 10.1038/s41586-024-07352-w
WOS ID 001207800900027
Scopus ID 85191237997
PubMed ID 38658764
Erfassungsdatum 2024-06-11
[➜Korrektur melden]